For research use only. Not for therapeutic Use.
Trilaciclib (Cat No.: I011412) is a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It exerts its pharmacologic action by specifically binding to and inhibiting CDK4/6, enzymes involved in cell cycle progression. Trilaciclib has been developed as a myelopreservation agent with the potential to protect hematopoietic stem and progenitor cells from the damaging effects of chemotherapy. By temporarily inducing cell cycle arrest in these cells, trilaciclib aims to reduce chemotherapy-induced myelosuppression, including neutropenia and thrombocytopenia. Trilaciclib is being investigated as a supportive care therapy to enhance the tolerability and reduce the side effects of chemotherapy in patients with various types of cancer.
| Catalog Number | I011412 |
| CAS Number | 1374743-00-6 |
| Synonyms | G1T28; 2/’-[[5-(4-Methylpiperazin-1-yl)pyridin-2-yl]amino}-7/’,8/’-dihydro-6/’H-spiro[cyclohexane-1,9/’-pyrazino[1/’,2/’:1,5]pyrrolo[2,3-d]pyrimidin]-6/’-one; |
| Molecular Formula | C24H30N8O |
| Purity | 98% |
| Target | CDK4/6 |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one |
| InChI | InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29) |
| InChIKey | PDGKHKMBHVFCMG-UHFFFAOYSA-N |
| SMILES | CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6 |
| Reference | 1: Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC. Preclinical |
